Market Growth and Industry Potential - The VDS industry in China has a growth potential of six times, with a current market size exceeding 460 billion RMB and an industry growth rate of 10%-15%[4] - The VDS market in China is still developing, with per capita consumption and penetration rates significantly lower than those in developed countries[4] - The VDS retail growth rate in Chinese pharmacies dropped from 5.4% in 2017 to only 0.8% in 2019, indicating a pressing need for industry recovery[5] - The "Health China 2030" national strategy aims to shift focus from disease treatment to health promotion, presenting significant growth opportunities for the nutrition and health industry[4] - The company aims to transition from "squeezed growth" to leading a restorative growth phase for the entire VDS industry[5] Company Strategy and Operations - The company emphasizes the importance of consumer trust and transparency, having established a global leading VDS manufacturing base and a transparent factory[4] - The company has identified "activation" as the key strategy for 2020, focusing on revitalizing both personnel and the VDS business[5] - The company will continue to focus on "user asset operation," "e-commerce digitalization," and "super supply chain" as key strategic projects for future growth[6] - The company is upgrading its distributor system to support the operation of multiple major products and new brands[14] - The company plans to enhance brand strength by increasing investment in brand assets[6] Financial Performance - The company reported its first loss since listing due to goodwill impairment[6] - The company’s operating revenue for 2019 was CNY 5,261,799,439.25, representing a 20.94% increase from CNY 4,350,775,627.15 in 2018[30] - The net profit attributable to shareholders for 2019 was CNY -355,889,615.46, a decrease of 135.51% compared to CNY 1,002,184,999.85 in 2018[30] - The basic earnings per share for 2019 was CNY -0.24, down 134.78% from CNY 0.69 in 2018[30] - The company reported a significant adverse impact on its 2019 performance due to the impairment of goodwill and intangible assets related to LSG, totaling RMB 1,081.57 million[19] Research and Development - The company has focused on expanding its product offerings, including new formulations and delivery methods for health products[46] - The company published 47 research papers in 2019, enhancing its academic influence and promoting a vibrant academic atmosphere[54] - The company is actively involved in research related to dietary fibers and their effects on health, as evidenced by multiple publications in relevant journals[55] - The company aims to enhance its market presence through the introduction of innovative health products and scientific research[54] - The company has established six provincial-level and above innovation research platforms, enhancing its research capabilities[79] Regulatory Environment and Compliance - The regulatory environment for the VDS industry in China is among the strictest globally, impacting product safety, efficacy, and market access[3] - The company continues to focus on regulatory compliance and product innovation to maintain its competitive edge in the health food market[52] - The company has maintained compliance with its commitments as of the reporting period[131] - The company has ensured that all documents related to the asset purchase are accurate and complete, with no misleading statements or omissions[132] - The company has committed to fulfilling legal disclosure and reporting obligations, ensuring no undisclosed contracts or agreements exist[139] Acquisitions and Investments - The company completed the cash acquisition of Life-Space Group (LSG) in August 2018, gaining 100% control by July 31, 2019, and is focusing on integrating financial management, customer management, and resource management to achieve synergy[18] - The company is actively exploring new brands and businesses in the consumer health sector, although the commercial and profit models for these new ventures carry significant uncertainty[17] - The company has committed to ensuring the accuracy and completeness of financial and operational information as part of its asset restructuring promises[131] - The company has made a significant equity investment of CNY 30,000,000 in Hong Kong Baihong Limited, acquiring a 100% stake[90] - The company has established strategic cooperation agreements with BASF and DuPont for research and development in precision nutrition and probiotics, respectively, with ongoing projects since 2017 and 2019[172][173] Social Responsibility and Community Engagement - The company has actively engaged in social responsibility initiatives, including the "1+1+Hope Project," which has built 16 Hope primary schools and is currently constructing the 17th[174] - In response to the COVID-19 pandemic, the company donated 10 million yuan to establish a special fund and provided over 65,000 nutritional supplement packages to hospitals and healthcare workers[175] - The company emphasizes a dual focus on economic and social benefits, ensuring compliance with laws and regulations while supporting local economic development[174] - The company has conducted nearly 3,500 public welfare activities under the "Healthy Fast Track Nutrition China" initiative since 2011[174] - The company reported no instances of environmental violations during the reporting period and adheres strictly to environmental protection laws[176] Shareholder Returns and Dividends - The company plans to distribute a cash dividend of RMB 3.60 per 10 shares, based on a total share capital of 1,582,492,554 shares[129] - The cash dividend policy aligns with the company's articles of association and has been approved by the board and shareholders[127] - The company has maintained a cash dividend ratio exceeding 30% of the average distributable profit over the last three years, ensuring the protection of minority shareholders' interests[125] - The company is in a growth phase and plans to allocate at least 20% of profits for cash dividends despite significant capital expenditures[128] - The company’s net profit for 2019 was reported as -355,889,615.46, indicating financial challenges faced during the year[130]

Financial Performance - Operating revenue for the reporting period reached ¥1,411,194,136.66, representing a year-on-year increase of 12.73%[3] - Net profit attributable to shareholders was ¥324,088,641.05, reflecting a decrease of 8.30% compared to the same period last year[3] - Basic earnings per share for the reporting period was ¥0.21, down 12.50% year-on-year[3] - The weighted average return on equity was 4.96%, a decrease of 1.50% compared to the previous year[3] - Cash flow from operating activities for the reporting period was ¥286,448,048.55, a decrease of 16.34% year-on-year[3] - The company's operating revenue for the first nine months of the year reached CNY 438,096.91 million, an increase of 28.04% compared to the same period last year[10] - The net profit attributable to shareholders for the same period was 1.191 billion yuan, reflecting a year-on-year growth of 12.56%[12] - Total operating revenue for Q3 2019 reached ¥1,411,194,136.66, an increase of 12.76% compared to ¥1,251,797,198.49 in the same period last year[36] - The net profit for the third quarter of 2019 was CNY 186,882,176.77, down 11.2% from CNY 210,320,172.02 in the previous year[41] - The total comprehensive income attributable to the parent company was CNY 1,212,135,775.38, compared to CNY 1,060,815,082.50 in the previous year, marking a growth of 14.3%[44] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥9,663,314,068.46, a decrease of 1.30% compared to the end of the previous year[3] - The company's accounts receivable at the end of the period amounted to CNY 44,906.93 million, up 102.77% from the beginning of the year, primarily due to increased sales volume[10] - The company's total liabilities decreased by 33.28% to CNY 22,629.22 million, primarily due to payments made for last year's inventory[10] - Total current assets decreased to ¥3,496,899,062.43 from ¥4,095,633,719.45, a decline of approximately 14.6% year-over-year[29] - Total liabilities decreased to ¥2,337,609,314.74 from ¥2,902,496,202.91, a decline of approximately 19.5%[31] - The total assets of the company stand at CNY 9,790,445,489.84, showcasing its financial strength[58] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was not specified, but the top ten shareholders held significant stakes[6] - The largest shareholder, Liang Yunchao, held 710,611,742 shares, with a portion being pledged[6] - The company did not engage in any repurchase transactions during the reporting period[7] Research and Development - The company's R&D expenses for the first nine months amounted to CNY 8,169.25 million, an increase of 34.13% year-on-year, driven by multiple ongoing R&D projects[10] - Research and development expenses for the quarter were ¥30,189,880.72, up from ¥27,836,892.32 in Q3 2018, reflecting a commitment to innovation[36] - Research and development expenses increased to CNY 73,309,721.72, up 36.3% from CNY 53,837,602.12 in the same quarter last year[46] Market Strategy and Challenges - The company is actively expanding its e-commerce branding strategy, aiming for a comprehensive integration of sales channels[12] - The company faces challenges from regulatory actions in the health supplement industry, which are expected to have a long-term impact on the market[12] - The company is committed to enhancing product quality and safety, implementing strict quality management measures and emergency response plans[13] - The company acknowledges the intensified competition in the industry due to the entry of international brands and large pharmaceutical companies[14] Acquisitions and Investments - The company completed the acquisition of 100% equity in Guangzhou Tangchen Baisheng Co., Ltd. through a share issuance, with the approval from the China Securities Regulatory Commission on July 2, 2019[19] - The company is expanding its market presence through acquisitions, including the children's nutrition supplement brand "Penta-vite" and the Australian probiotic brand "Life-Space"[12] - The company has implemented specific integration measures for LSG, focusing on financial management, customer management, and resource allocation to achieve synergies[17] Financial Management - The company's financial expenses for the first nine months were CNY 1,456.44 million, an increase of 153.78% year-on-year, mainly due to interest expenses from acquisition loans[10] - The company incurred financial expenses of CNY 14,564,428.47 for the year-to-date period, compared to a financial income of CNY 27,082,378.05 in the previous year[42] - The company reported a decrease in credit impairment losses to CNY -25,210.76 from CNY -19,275,198.51 in the previous year, showing improved asset quality[46] Cash Flow - Cash flow from operating activities was CNY 4,390,403,618.76, compared to CNY 3,614,755,295.91 in the previous year, indicating a significant increase[48] - Net cash flow from operating activities was CNY 757,431,075.10, down from CNY 914,453,771.93, indicating a decline of about 17.2%[49] - Cash inflow from investment activities was CNY 1,110,410,808.70, significantly lower than CNY 3,092,783,435.73 in the previous year, representing a decrease of approximately 64.1%[50] Other Information - The company has not reported any violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[26] - The company is preparing for potential significant changes in net profit compared to the previous year, indicating a cautious outlook for future performance[25] - The company established Hong Kong Bai'ao Co., Ltd. with an investment of 1 HKD on August 22, 2019, primarily for investment holding purposes[23]

Financial Performance - The company reported a revenue increase of 15% year-on-year for the first half of 2019, reaching approximately RMB 1.2 billion[6]. - Total revenue for the first half of 2019 reached ¥2,969,774,935.37, representing a 36.88% increase compared to ¥2,169,666,705.82 in the same period last year[22]. - Net profit attributable to shareholders was ¥866,851,366.08, up 23.03% from ¥704,607,102.68 in the previous year[22]. - Net profit after deducting non-recurring gains and losses was ¥848,597,310.20, reflecting a 26.67% increase from ¥669,948,590.56 year-on-year[22]. - Basic earnings per share increased to ¥0.59, a rise of 22.92% compared to ¥0.48 in the same period last year[22]. - The company has set a revenue guidance of RMB 2.5 billion for the full year 2019, representing a growth target of 12%[6]. - The company achieved a revenue of 2.97 billion CNY in the first half of 2019, representing a year-on-year growth of 36.88%[37]. - The main brand "汤臣倍健" saw a revenue growth of 14.44%, while the joint care brand "健力多" experienced a significant increase of 53.71%[37]. User Growth and Market Strategy - User data indicates a growth in active users by 20%, with a total of 5 million active users as of June 30, 2019[10]. - The company plans to expand its product line by launching three new health supplement products in the second half of 2019[10]. - The company is actively expanding its e-commerce branding efforts to achieve full-channel integration and innovation[27]. - The company is focusing on three major product strategies, including the promotion of "健力多," "健视佳," and "Life-Space" to expand market reach[40]. - The company aims to transition from a single product provider to a comprehensive health intervention solution provider, focusing on high-quality and differentiated product offerings[27]. Financial Position and Assets - The company's total assets as of June 30, 2019, were ¥9,594,515,938.11, a decrease of 2.00% from ¥9,790,445,489.84 at the end of the previous year[23]. - Net assets attributable to shareholders increased by 3.01% to ¥5,759,903,328.69 from ¥5,591,786,199.13 at the end of the previous year[23]. - The company's cash and cash equivalents at the end of the reporting period were CNY 1.96 billion, accounting for 20.40% of total assets[54]. - The company reported a significant increase of 236.25% in construction in progress, totaling CNY 208.29 million, mainly for the construction of a nutrition exploration center[55]. - The company’s total assets at the end of the reporting period were CNY 7,016,228,819.44, indicating a stable asset base[128]. Costs and Expenses - The gross profit margin for the first half of 2019 was reported at 45%, a slight decrease from 47% in the same period last year due to rising raw material costs[7]. - Operating costs increased by 42.14% to RMB 950,022,252.60, primarily due to the rise in sales[50]. - Sales expenses rose by 50.75% to RMB 743,911,106.15, attributed to increased brand investment and consolidation of LSG[50]. - Research and development investment grew by 46.28% to RMB 48,568,572.23, driven by multiple ongoing R&D projects[50]. Acquisitions and Investments - The company has completed the acquisition of Life-Space Group Pty Ltd, with an integration plan focusing on financial and operational synergies[11]. - The company has acquired children's nutritional supplement brand "Penta-vite" and Australian probiotic brand "Life-Space" to enhance its brand matrix[27]. - The company did not make any significant equity investments during the reporting period, with a total investment amount of CNY 0[58]. - The company reported a significant related party transaction involving procurement from Dongtai Cibainian Biological Co., amounting to 613,200 RMB, which represents 0.06% of similar transaction amounts[86]. Shareholder and Equity Information - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[12]. - The company completed the cancellation of 54,000 restricted stocks, reducing the total share capital from 1,468,817,880 shares to 1,468,763,880 shares[20]. - The total number of shares decreased from 1,468,817,880 to 1,468,763,880, a reduction of 54,000 shares[100]. - The company approved the cancellation of shares at the 2018 annual general meeting, with 99.9638% of votes in favor[102]. Regulatory and Compliance Matters - The company applied to the China Securities Regulatory Commission (CSRC) to suspend the review of its share issuance for asset acquisition on May 15, 2019[94]. - The company received multiple feedback notices from the CSRC regarding its asset acquisition application throughout early 2019, indicating ongoing regulatory scrutiny[95]. - The company’s stock was suspended on April 16, 2019, due to the review of its asset acquisition application by the CSRC[95]. - The company has not faced any media scrutiny or legal penalties during the reporting period[77]. Research and Development - The company is in normal execution of its strategic cooperation agreements for R&D with BASF and Bioiberic, focusing on precise nutrition and functional health products[89]. - Research and development expenses rose to ¥51,502,576.97, a 56% increase from ¥33,069,646.63 in the first half of 2018[118]. - The company capitalizes expenses related to health food registration and inspection fees for new product projects, indicating a focus on regulatory compliance[187]. Cash Flow and Financial Management - The net cash flow from operating activities was ¥480,068,086.46, down 18.79% from ¥591,108,757.19 in the same period last year[22]. - The net increase in cash and cash equivalents was approximately CNY 144.60 million, a decrease of 114.27% compared to the previous year[51]. - The cash flow from operating activities showed a positive trend despite the overall decrease in net cash flow, indicating potential for future growth[127]. - The company’s financial statements are prepared in accordance with the Chinese Accounting Standards and reflect the financial status, operating results, and cash flows accurately[140].

Financial Performance - Total revenue for Q1 2019 reached ¥1,571,070,999.36, an increase of 47.17% compared to ¥1,067,528,780.45 in the same period last year[5] - Net profit attributable to shareholders was ¥497,464,007.84, up 33.69% from ¥372,090,907.60 year-on-year[5] - Net profit excluding non-recurring gains and losses was ¥488,983,719.01, reflecting a 32.65% increase from ¥368,638,242.42 in the previous year[5] - Basic earnings per share rose to ¥0.34, a 36.00% increase compared to ¥0.25 in the same period last year[5] - The weighted average return on equity was 8.63%, up from 7.10% year-on-year, representing an increase of 1.53%[5] - The company's operating revenue for the period was 1,571.07 million CNY, representing a year-on-year increase of 47.17%, driven by strong sales performance[13] - The net profit attributable to shareholders of the listed company was 497 million CNY, up 33.69% year-on-year[13] - Operating profit for Q1 2019 was ¥634,044,176.36, compared to ¥495,223,832.81 in Q1 2018, indicating an increase of about 28.1%[36] - The total comprehensive income for Q1 2019 was ¥437,766,987.28, compared to ¥373,526,750.22 in the same period last year, reflecting an increase of approximately 17.2%[36] Assets and Liabilities - Total assets at the end of the reporting period were ¥10,333,672,722.09, a 5.55% increase from ¥9,790,445,489.84 at the end of the previous year[5] - Total liabilities rose to CNY 3,718,163,827.87 from CNY 2,902,496,202.91, indicating an increase of approximately 28.14%[31] - Current liabilities totaled CNY 2,328,877,461.93, up from CNY 1,491,182,092.40, reflecting a growth of about 56.06%[31] - Total liabilities as of Q1 2019 amounted to ¥2,352,427,838.49, compared to ¥1,215,028,239.72 in the previous year, showing an increase of about 93.5%[34] - The total equity for the company was ¥5,694,475,860.10 in Q1 2019, slightly down from ¥5,732,643,422.92 in the same period last year, a decrease of approximately 0.7%[34] Cash Flow - The net cash flow from operating activities was ¥7,245,233.28, a significant decrease of 94.06% compared to ¥121,997,320.18 in the same period last year[5] - The company's cash flow from operating activities was ¥7,245,233.28, compared to ¥121,997,320.18 in the previous period, showing a decrease in net cash flow[41] - The cash inflow from operating activities totaled ¥1,344,975,866.97, an increase from ¥992,526,577.68 in the previous period, representing a growth of about 35.5%[41] - The cash outflow for operating activities was ¥1,337,730,633.69, compared to ¥870,529,257.50 in the previous period, indicating an increase of approximately 53.6%[41] - The company reported investment cash inflows of ¥875,000,000.00 from recovered investments, up from ¥300,000,000.00 in the previous period, marking a growth of about 191.7%[41] Shareholder Information - The company had a total of 35,289 common shareholders at the end of the reporting period[8] - The largest shareholder, Liang Yunchao, held 48.38% of the shares, totaling 710,611,742 shares[8] Strategic Initiatives - The company has acquired children's nutritional supplement brand "Penta-vite" and Australian probiotic brand "Life-Space" to enhance its brand portfolio[13] - The company plans to enhance its market strategy by launching a brand upgrade strategy centered around protein powder and expanding its e-commerce capabilities[13] - The company has initiated a brand enhancement strategy centered around protein powder as its flagship product[15] - The company plans to accelerate the construction of smart factories and deepen the development of maternal and infant channels[15] - The company is actively seeking alternative suppliers to mitigate risks associated with rising raw material prices and potential shortages[16] Risks and Compliance - The company faces risks related to product quality and food safety, emphasizing the importance of quality management and compliance with national standards[15] - The company recognizes the risk of goodwill impairment if effective integration and synergy are not achieved post-acquisition[16] - The company reported no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[23] - The company has not reported any violations regarding external guarantees during the reporting period[27] Investment and Projects - The company completed the acquisition of Life-Space Group Pty Ltd, with ongoing efforts to integrate operations and achieve synergies[16] - The total amount of funds raised was 183,012.19 million CNY, with 8,051.81 million CNY invested in the current quarter[24] - The Zhuhai production base phase IV construction project has an investment progress of 88.18% with a total investment of 43,001.00 million CNY[24] - The company has decided to use CNY 55 million of the remaining raised funds for the acquisition of 100% of Life-Space Group Pty Ltd, which has been approved by the board[25] - The company has implemented lean management at its Zhuhai production base, significantly enhancing production efficiency[25] Financial Adjustments - The first quarter report was not audited, indicating preliminary financial data[54] - The company adopted retrospective adjustments for financial instruments and leasing standards, impacting previous financial statements[52] - The company reported a decrease in other current assets by CNY 1,035,000,000.00 due to reclassification of financial assets[53]

Financial Performance - The company's operating revenue for 2018 was approximately ¥4.35 billion, representing a 39.86% increase compared to ¥3.11 billion in 2017[21]. - The net profit attributable to shareholders for 2018 was approximately ¥1.00 billion, a 30.79% increase from ¥766 million in 2017[21]. - The net profit after deducting non-recurring gains and losses was approximately ¥914 million, reflecting a 41.89% increase from ¥644 million in the previous year[21]. - The net cash flow from operating activities for 2018 was approximately ¥1.35 billion, up 41.36% from ¥954 million in 2017[21]. - The total assets at the end of 2018 were approximately ¥9.79 billion, a 60.14% increase from ¥6.11 billion at the end of 2017[21]. - The net assets attributable to shareholders at the end of 2018 were approximately ¥5.59 billion, a 9.63% increase from ¥5.10 billion at the end of 2017[21]. - The basic earnings per share for 2018 was ¥0.69, which is a 32.69% increase compared to ¥0.52 in 2017[21]. - The diluted earnings per share for 2018 was also ¥0.69, reflecting the same percentage increase as the basic earnings per share[21]. - The weighted average return on equity for 2018 was 19.00%, an increase of 3.20% from 15.80% in 2017[21]. - The company achieved a total revenue of ¥4,350,775,627.15 in 2018, representing a 39.86% increase compared to ¥3,110,795,387.73 in 2017[65]. Dividend Policy - The company reported a profit distribution plan to distribute a cash dividend of 5.00 RMB (including tax) for every 10 shares based on a total of 1,468,817,880 shares[10]. - The proposed cash dividend for 2018 is RMB 5.00 per 10 shares, based on a total share capital of 1,468,817,880 shares[124]. - Total cash dividends for 2018 amounted to RMB 734,408,940.00, representing 73.28% of the net profit attributable to shareholders[125]. - The cash dividend payout ratio has exceeded 30% of the average distributable profit over the last three years[124]. - The company plans to continue implementing a proactive profit distribution policy to enhance investor returns[130]. - The cash dividend for 2017 was RMB 484,859,720.40, which was 63.28% of the net profit for that year[125]. - The cash dividend for 2016 was RMB 382,283,688.80, representing 71.43% of the net profit[125]. Acquisitions and Investments - The company completed the cash acquisition of Life-Space Group Pty Ltd (LSG) in August 2018, which requires integration efforts due to differences in legal, accounting, and cultural practices[9]. - The company acquired 100% of Life-Space Group Pty Ltd, enhancing its capabilities in the probiotic segment and achieving control on August 30, 2018[55]. - The acquisition of Bayer's Penta-vite business assets further strengthened the company's position in the children's nutrition market[55]. - The company acquired the "Penta-vite" brand and Life-Space Group Pty Ltd to enhance its product portfolio[50]. - The company has pledged equity for loan guarantees, including 100% equity of LSG held by Australia Baisheng and 100% equity of Australia Baisheng held by Hong Kong Baisheng[87]. - The company made a significant equity investment of ¥105,000,000 in Guangzhou Weilai Zhuoshi Equity Investment Fund, holding a 29.70% stake[89]. Market Strategy and Expansion - The company is expanding its market presence and sales management practices to address the risks associated with increased market control and competition[6]. - The company is transitioning from product marketing to value marketing, aiming to provide comprehensive health intervention solutions[7]. - The company aims to enhance its brand value through acquisitions, having successfully acquired children's nutritional supplement brand "Pentavite" and Australian probiotic brand "Life-Space"[29]. - The company is focused on expanding its market presence in segments such as joint care, probiotics, children's nutrition, and sports nutrition, leveraging its core competencies in product, brand, channel, and service[29]. - The company plans to enhance its brand strategy by promoting protein powder as a flagship product, targeting younger consumers to solidify its market leadership[106]. - The company will further develop its "big single product" strategy, aiming for greater sales of its key products, including "Jianli Duo" and "Jian Shijia," while expanding the distribution of Life-Space products[107]. Research and Development - The company has focused on research and development, completing multiple technology projects and encouraging employee participation in scientific research[47]. - The company has established a robust framework for intellectual property management, evidenced by the significant number of trademarks and health food certifications obtained[42][45]. - The company will establish a "Nutrition Anti-Aging Research Center" and an "Overseas R&D Center" in 2019 to strengthen its R&D capabilities and maintain technological leadership in the industry[112]. - The company is committed to continuous innovation, as evidenced by its new patents related to health products and packaging designs[38][39][40]. - The company has a commitment to focus on "new functions, new materials, and new technologies" in its innovative research and development efforts[165]. Risk Management - The company faces risks related to raw material procurement, including potential price increases and supply shortages, which could impact production costs and sales[5]. - The company acknowledges the risks associated with new business ventures and brands, which may have uncertain commercial and profit models[8]. - The company has identified potential goodwill impairment risks related to the acquisition of LSG if effective integration is not achieved[10]. - The company is committed to maintaining high-quality standards that exceed national regulations to mitigate product quality risks[3]. Corporate Governance and Compliance - The company has adhered to all legal and regulatory requirements, including the Company Law and Securities Law, in its governance practices[131]. - The company has maintained its independent operations and governance structure, ensuring no competition or unfair transactions with its actual controller[131]. - The company has ensured compliance with all commitments made regarding the avoidance of conflicts of interest and related party transactions[133]. - The company has committed to measures that will ensure the fulfillment of return compensation mechanisms, linking them to the execution of equity incentive plans[132]. - The company has maintained a clean record with no criminal investigations or regulatory inquiries in the past year, reinforcing its operational integrity[132]. Social Responsibility - The company has built 16 Hope primary schools since 2005, with 14 completed by 2018, as part of its corporate social responsibility initiatives[166]. - The company has conducted nearly 3,000 public welfare activities under the "Healthy Express Nutrition China Tour" project since 2011[166]. - The company provided free nutritional enhancement formula powder to 6,500 students in 18 rural primary schools across Guangdong, Hubei, and Hebei provinces as part of its nutrition improvement project[167]. - The company has donated nutritional products to over 140 primary schools and trained 410 nutrition teachers, benefiting nearly 50,000 students[167].

汤臣倍健股份有限公司 2018 年第三季度报告 证券代码：300146 证券简称：汤臣倍健 公告编号：2018-123 2018 年第三季度报告 证券简称：汤臣倍健 证券代码：300146 披露日期：2018 年 10 月 1 汤臣倍健股份有限公司 2018 年第三季度报告 第一节 重要提示 1.公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在 虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 2.所有董事均已出席了审议本次季报的董事会会议。 3.公司负责人林志成先生、主管会计工作负责人吴卓艺女士及会计机构负责人（会计主管人员）黄蔚 女士声明：保证季度报告中财务报告的真实、准确、完整。 2 汤臣倍健股份有限公司 2018 年第三季度报告 第二节 公司基本情况 一、 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 9,591,989,336.81 | 6,113,609,64 ...

Acquisition and Restructuring - The company plans to acquire 100% of Life-Space Group Pty Ltd for no more than AUD 69 million, with the stock suspended since January 31, 2018, pending regulatory approvals[10] - The company initiated a major asset restructuring to acquire 100% of Life-Space Group Pty Ltd for no more than 69 million AUD, aiming to enhance its probiotic market presence[51] - The company announced a major asset restructuring plan, with the acquisition of 100% of Life-Space Group Pty Ltd for cash, which will become a wholly-owned subsidiary after the transaction is completed[113] - The company has expanded its children's nutrition segment by acquiring the Penta-vite brand from Bayer, enhancing its market positioning[51] Financial Performance - Total revenue for the reporting period reached ¥2,169,666,705.82, representing a 45.95% increase compared to ¥1,486,542,739.26 in the same period last year[25] - Net profit attributable to shareholders was ¥704,607,102.68, up 21.01% from ¥582,268,533.69 year-on-year[25] - Net profit after deducting non-recurring gains and losses was ¥669,948,590.56, reflecting a 42.28% increase from ¥470,863,693.60 in the previous year[25] - The net cash flow from operating activities was ¥591,108,757.19, an increase of 27.97% compared to ¥461,901,269.76 in the same period last year[25] - Basic earnings per share rose to ¥0.48, a 20.00% increase from ¥0.40 in the previous year[25] - The company reported a net profit of ¥119,078,306.96, with a revenue of ¥1,590,214,652.39, indicating a strong performance in the reporting period[85] - The company reported a net profit of CNY 1,003,000,000.0 for the current period, which represents a year-on-year growth of 14.8%[161] Market Strategy and Competition - The company is facing increased competition due to the entry of international brands and large pharmaceutical companies into the Chinese market, necessitating a strategic upgrade from product marketing to value marketing[8] - The company is focused on maintaining its market leadership by enhancing its core competencies in product, brand, channel, and service[8] - The company is transitioning from product marketing to value marketing, enhancing its comprehensive competitive capabilities[32] - The company aims to become a leading provider in the dietary supplement industry in China, emphasizing high-quality and differentiated products[32] - The company has implemented an e-commerce branding strategy 2.0, which has yielded significant results and opened new growth opportunities[32] Product Development and Innovation - The company is developing new products and exploring new sales growth points to address potential raw material shortages[6] - The company has 156 patents as of June 30, 2018, with 11 new patents added during the reporting period[36] - The company registered a total of 1,762 trademarks domestically, with 395 new trademarks registered in the reporting period[38] - The company has 144 approved certificates for nutritional supplements and health foods, with an increase of 11 certificates compared to the end of 2017[42] - The company is focusing on expanding its product offerings in bone health and sports nutrition segments[32] - The first major product "Jianli Duo" has established a strong position in the bone health segment, showing continuous market growth[47] Financial Management and Investments - The company reported a significant increase in asset impairment losses, which rose by 627.11% to ¥50,495,578.08, mainly due to the provision for impairment of intangible assets[59] - Investment income decreased by 92.05% to ¥9,624,910.93, primarily due to the previous year's sale of long-term equity investments[59] - The company has maintained a balance of 98,102.23 million yuan in unused raised funds, which are kept in a dedicated account[71] - The company plans to terminate the "Technical Operation Center Project" and redirect the remaining raised funds totaling CNY 203,918,754.96 to the "Terminal Refined Management and Brand Building Project" to maximize shareholder interests[75] - The company has allocated CNY 52,000,000.0 for research and development in new technologies and products[161] Regulatory Compliance and Governance - The company is committed to complying with new industry regulations and actively participates in the formulation and revision of industry laws and standards[4] - The company has not experienced any illegal or regulatory violations in the management of raised funds[71] - The company has not reported any overdue or unrecoverable amounts from entrusted wealth management[81] - The company has established a commitment to manage related party transactions in accordance with its articles of association[95] - The company is not subject to any major litigation or arbitration matters during the reporting period[98] Shareholder and Capital Management - The company has not declared any cash dividends or stock bonuses for the reporting period[11] - The company plans not to distribute cash dividends or issue bonus shares for the half-year period, focusing on reinvestment strategies[93] - The company completed the cancellation of 850,000 shares of restricted stock as of January 16, 2018, reducing the total share capital from 1,470,121,880 shares[99] - The company has implemented a stock incentive plan since 2016, which includes granting, listing, price adjustments, and repurchase of restricted shares[99] - The company committed to distributing at least 10% of the distributable profit as cash dividends over any three consecutive fiscal years, with a minimum total distribution of 30% of the average annual distributable profit for the last three years[96] Operational Challenges - The company has reported a risk related to raw material procurement, as rising prices may impact product gross margins, and it is actively seeking alternative suppliers[5] - The company is expanding its sales regions, which increases market control risks, and is implementing measures to enhance sales management and operations[7] - The company acknowledges the uncertainty surrounding new business models and joint ventures, particularly with its partner in the joint venture, Jianzhibao[9] Financial Reporting and Accounting Policies - The financial statements are prepared based on the going concern principle, indicating no significant issues affecting the company's ability to continue operations for at least 12 months from the reporting date[173] - The company adheres to the accounting policies and estimates in accordance with the "Enterprise Accounting Standards," ensuring the financial statements reflect a true and complete view of its financial position and performance[174] - The company uses Renminbi (RMB) as its functional currency for accounting purposes[177] - The company recognizes cash equivalents as short-term, highly liquid investments that are easily convertible to known amounts of cash[185]

Financial Performance - Total revenue for Q1 2018 reached ¥1,067,528,780.45, representing a 45.03% increase compared to ¥736,054,794.77 in the same period last year[7] - Net profit attributable to shareholders was ¥372,090,907.60, up 31.39% from ¥283,198,485.82 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥368,638,242.42, reflecting a 39.08% increase from ¥265,061,290.26 in the previous year[7] - Basic earnings per share increased to ¥0.25, a rise of 31.49% compared to ¥0.19 in the same period last year[7] - The company's revenue for the reporting period is 1,067.53 million RMB, an increase of 45.03% year-on-year, primarily due to sales growth[29] - The company's operating revenue for Q1 2018 was CNY 900.61 million, an increase of 50% compared to CNY 600.27 million in Q1 2017[70] - The net profit attributable to the parent company was CNY 372.09 million, up 31.4% from CNY 283.20 million in the same period last year[67] - The total profit for the quarter was CNY 495.25 million, representing a 40% increase from CNY 354.05 million in Q1 2017[66] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,306,116,789.08, a 3.15% increase from ¥6,113,609,642.75 at the end of the previous year[7] - The total liabilities for the company at the end of the reporting period are significantly impacted by a 194.59% increase in tax payable, totaling 146.77 million RMB[28] - Total liabilities rose to ¥1,281,117,582.02, up from ¥981,649,965.51, marking a significant increase of 30.6%[58] - The total equity attributable to shareholders decreased to ¥4,984,948,909.42 from ¥5,100,825,081.79, a decline of 2.27%[59] Cash Flow - The company reported a net cash flow from operating activities of ¥121,997,320.18, a decrease of 2.89% from ¥125,629,256.35 in the previous year[7] - The company reported a cash inflow from operating activities of CNY 956.58 million, compared to CNY 661.47 million in the same period last year[71] - Operating cash inflow for Q1 2018 was CNY 992.53 million, up from CNY 688.18 million in Q1 2017, representing an increase of 44.3%[73] - The ending balance of cash and cash equivalents reached CNY 2.85 billion, up from CNY 2.22 billion at the end of Q1 2017[74] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 62,603[20] - The largest shareholder, Liang Yunchao, holds 48.36% of the shares, totaling 710,611,742 shares, with 37,000,000 shares pledged[20] - The total number of restricted shares at the end of the period is 593,404,547 shares, with no new restrictions added during the reporting period[23] Strategic Initiatives - The company is in the process of acquiring 100% of Life-Space Group Pty Ltd for no more than AUD 69 million, with the stock currently suspended pending approval[18] - The company is focusing on solidifying its big product strategy and launching e-commerce branding 2.0 strategy in 2018[32] - The company aims to expand into niche markets such as bone health and sports nutrition while enhancing its e-commerce branding efforts[30] - The company is planning to adjust its strategies for mergers and acquisitions under overall strategic guidance[32] - The company is committed to building a transparent factory and a nutrition exploration center as part of its branding efforts[32] - The company is actively pursuing cross-border e-commerce strategies to initiate a new growth cycle[30] Operational Efficiency - The company's operating costs for the reporting period are 345.78 million RMB, reflecting a year-on-year increase of 33.99% due to sales growth[29] - The accounts receivable at the end of the period is 277.21 million RMB, up 79.50% from the beginning of the year, attributed to increased sales and credit limits granted to customers[27] - The prepayment balance at the end of the period is 29.07 million RMB, up 111.52% from the beginning of the year, mainly due to increased advance payments to suppliers[27] - The company's tax expenses for the reporting period are 16.16 million RMB, an increase of 82.58% year-on-year, driven by revenue growth[29] - The company's investment income for the reporting period is 2.01 million RMB, a decrease of 93.34% year-on-year, mainly due to last year's equity transfer gains[29] Compliance and Governance - The company has not reported any non-compliance with external guarantees during the reporting period[51] - There are no overdue commitments from actual controllers, shareholders, or related parties during the reporting period[43] - The company’s cash dividend policy is in line with regulatory requirements, with a distribution of RMB 3.30 per 10 shares approved for the 2017 fiscal year[50]

Financial Performance - The company's revenue for 2017 reached ¥3,110,795,387.73, representing a 34.72% increase compared to ¥2,309,112,366.04 in 2016[23]. - Net profit attributable to shareholders was ¥766,255,562.79, up 43.17% from ¥535,211,834.09 in the previous year[23]. - The net cash flow from operating activities increased by 39.39% to ¥954,308,997.11 from ¥684,648,483.86 in 2016[23]. - Basic earnings per share rose to ¥0.52, a 40.54% increase from ¥0.37 in 2016[23]. - Total assets at the end of 2017 were ¥6,113,609,642.75, reflecting a 14.74% growth from ¥5,328,358,061.19 in 2016[23]. - The company achieved operating revenue of 3,110.80 million yuan, a year-on-year increase of 34.72%[34]. - The company reported a significant non-operating income of ¥122,227,234.50 for 2017, compared to ¥59,382,400.63 in 2016[29]. - The weighted average return on equity increased to 15.80% from 11.76% in the previous year[23]. Market Strategy and Expansion - The company is planning to acquire 100% of Life-Space Group Pty Ltd for no more than 69 million AUD, pending necessary approvals[12]. - The company is expanding its market presence and enhancing sales management to address the increasing complexity of market control[9]. - The company is transitioning from product marketing to value marketing, aiming to become a comprehensive health intervention solution provider[10]. - The company is actively exploring new business models and integrating industry resources to support innovation[11]. - The company acknowledges the risks associated with intensified competition from international brands and large pharmaceutical companies entering the market[10]. - The company plans to continue expanding its market presence and invest in new product development[23]. - The company has established a "Nutrition Family" membership store system to provide added value services to distributors and retailers, expanding its offline competitive advantage[40]. - The company initiated an e-commerce branding strategy, introducing exclusive products for online channels to maintain and expand its leading position in the health food category[64]. Product Development and Innovation - The company is focused on developing new products and exploring alternative raw materials to meet production demands[8]. - The company holds 144 health food approval certificates and 50 health food filing certificates as of the end of 2017, indicating strong product development efforts[38]. - The company owns 145 patents, with 57 new patents added during the reporting period, showcasing its commitment to innovation[44]. - The company aims to enhance its product offerings through the development of new packaging designs for various health supplements, ensuring compliance with market trends[45]. - The company’s innovation pipeline includes a variety of new product designs aimed at enhancing customer experience and satisfaction[45]. - The company launched several new health food products in 2017, including "Beijian® Vitamin E with Vitamin C Chewable Tablets" and "Taochen Beijian® Calcium Iron Multivitamin Tablets (Pregnant and Nursing Women Type)"[51]. - The company has maintained a focus on research and development, as evidenced by its commitment to publishing scientific papers and undertaking technology projects[56]. Financial Management and Investments - The company has no outstanding debts as of the reporting period[24]. - The company reported investment income of CNY 125,867,763.95, accounting for 14.22% of total profit[99]. - The company has committed to using raised funds strictly according to regulations, with no violations reported[115]. - The company has ongoing significant non-equity investments, as indicated in the fundraising usage section[110]. - The company has made investments in new product development and market expansion, particularly in the microalgae cultivation sector[109]. - The company reported a total investment of 151,601.79 million in various projects, with a significant portion allocated to brand building and production capacity expansion[119]. Corporate Governance and Shareholder Relations - The company has committed to maintaining a minimum cash dividend ratio of 20% during its growth phase, despite significant capital expenditure plans[151]. - The cash dividend policy has been consistent with the company's articles of association and has been approved by the shareholders' meeting, ensuring the protection of minority shareholders' rights[149]. - The independent directors believe the profit distribution plan aligns with the company's actual situation and benefits shareholders, especially minority shareholders[154]. - The profit distribution plan is subject to approval at the 2017 annual general meeting of shareholders[154]. - The company has actively engaged in various communication activities with institutions to discuss operational performance and market strategies throughout 2017[144]. Social Responsibility and Community Engagement - The company is actively fulfilling its corporate social responsibility, focusing on performance, compliance, product quality, and community development[182]. - The company has initiated various public welfare projects, including the "Hope Project" and "Nutrition Improvement Project" for children in poverty-stricken areas[183]. Risk Management - The company faces risks related to raw material procurement, which may impact production costs and sales of key products[8]. - The company emphasizes quality management and has invested in precision inspection equipment to mitigate product quality risks[5]. - The company is committed to complying with evolving industry regulations to ensure sustainable growth[6].

Financial Performance - Net profit attributable to shareholders reached ¥220,963,799.48, up by 5.74% year-on-year[7] - Total operating revenue for the period was ¥863,684,131.84, reflecting a 27.11% increase compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥220,700,366.98, an increase of 12.04% year-on-year[7] - Basic earnings per share were ¥0.15, representing a growth of 7.14% compared to the same period last year[7] - The company’s net profit for the year-to-date reached ¥803,232,333.17, up by 41.48% compared to the same period last year[7] - Net profit for the quarter was ¥230,496,677.72, representing a 14.0% increase from ¥202,161,540.84 in the previous year[39] - The net profit attributable to shareholders of the parent company was ¥220,963,799.48, compared to ¥208,966,634.14 in the same quarter last year, reflecting a growth of 5.7%[39] - Net profit for the current period was ¥827,574,869.65, a rise of 49.5% compared to ¥553,433,503.75 in the same period last year[45] Revenue and Costs - Total operating revenue for the third quarter reached ¥863,684,131.84, an increase of 27.1% compared to ¥679,486,138.97 in the same period last year[38] - Total operating costs amounted to ¥593,177,581.65, up 32.0% from ¥449,311,451.78 year-on-year[38] - Total operating revenue for the current period reached ¥2,350,226,871.10, an increase of 22.8% compared to ¥1,912,817,240.13 in the previous period[44] - Total operating costs amounted to ¥1,502,217,511.53, up 16.0% from ¥1,295,141,112.43 in the prior period[44] Assets and Liabilities - Total assets increased to ¥5,871,244,401.29, representing a growth of 10.19% compared to the end of the previous year[7] - Total current assets increased to ¥3,872,837,259.96 from ¥3,229,510,871.69, representing a growth of approximately 19.9%[30] - Total non-current assets decreased to ¥1,998,407,141.33 from ¥2,098,847,189.50, a decline of about 4.8%[31] - Total liabilities increased to ¥718,460,097.69 from ¥624,661,168.34, indicating a rise of approximately 15.1%[32] - Total liabilities increased to ¥394,833,481.41, compared to ¥349,699,595.18 in the same period last year, marking an increase of 12.9%[39] - Total equity rose to ¥5,152,784,303.60 from ¥4,703,696,892.85, showing an increase of about 9.5%[32] - Total equity rose to ¥5,038,209,400.93, up from ¥4,728,434,502.70 year-on-year, indicating a growth of 6.5%[39] Cash Flow - The company reported a net cash flow from operating activities of ¥642,707,877.88, which is a 24.05% increase year-to-date[7] - Cash inflows from operating activities totaled ¥2,522,653,508.96, an increase from ¥2,041,960,231.19 in the previous period[48] - The net cash flow from operating activities for the third quarter was CNY 642.71 million, an increase of 24% compared to CNY 518.12 million in the same period last year[50] - The company reported a total cash inflow from operating activities of CNY 1.51 billion, an increase of 37% from CNY 1.10 billion year-on-year[52] - The net cash flow from financing activities was negative CNY 378.57 million, compared to negative CNY 173.38 million in the previous year[53] Investments - Investment income for the first three quarters was CNY 121.03 million, a substantial increase of 255.46% year-on-year, primarily from the sale of equity in Shenzhen Beitai and Shanghai Vandi[19] - The company plans to transfer its entire 8.6498% stake in Shenzhen Youkashu Technology Co., Ltd. for CNY 294.09 million, with payment to be made through the issuance of shares[23] - The company’s long-term equity investments decreased by 50.20% to CNY 109.63 million, primarily due to the sale of equity stakes in Shenzhen Beitai and Shanghai Vandi[18] - The company reported a decrease in financial expenses, with a net financial income of -¥36,111,423.81 compared to -¥29,720,568.09 in the previous period[44] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 68,721[11] - Major shareholder Liang Yunchao holds 48.34% of the shares, with 532,958,806 shares pledged[11]